Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
13.73
+0.30 (2.23%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Inhibrx Employees
Inhibrx had 172 employees as of December 31, 2023. The number of employees increased by 31 or 21.99% compared to the previous year.
Employees
172
Change (1Y)
31
Growth (1Y)
21.99%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
198.75M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 172 | 31 | 21.99% |
Dec 31, 2022 | 141 | 29 | 25.89% |
Dec 31, 2021 | 112 | 21 | 23.08% |
Dec 31, 2020 | 91 | 11 | 13.75% |
Dec 31, 2019 | 80 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Accuray | 1,024 |
908 Devices | 230 |
Biodesix | 217 |
Alpha Teknova | 211 |
Rigel Pharmaceuticals | 147 |
OptimizeRx | 136 |
Fractyl Health | 94 |
Candel Therapeutics | 42 |
INBX News
- 7 weeks ago - Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
- 2 months ago - Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi - PRNewsWire
- 2 months ago - Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off - PRNewsWire
- 2 months ago - INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX - Business Wire
- 2 months ago - Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger - PRNewsWire
- 5 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PRNewsWire
- 6 months ago - Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi - PRNewsWire
- 6 months ago - Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline - Investopedia